DE60027564D1 - Tek-antagonisten - Google Patents

Tek-antagonisten

Info

Publication number
DE60027564D1
DE60027564D1 DE60027564T DE60027564T DE60027564D1 DE 60027564 D1 DE60027564 D1 DE 60027564D1 DE 60027564 T DE60027564 T DE 60027564T DE 60027564 T DE60027564 T DE 60027564T DE 60027564 D1 DE60027564 D1 DE 60027564D1
Authority
DE
Germany
Prior art keywords
tek antagonists
methods
tek
antagonists
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027564T
Other languages
English (en)
Other versions
DE60027564T3 (de
DE60027564T2 (de
Inventor
P Cerretti
G Borges
C Fanslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22479496&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60027564(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE60027564D1 publication Critical patent/DE60027564D1/de
Application granted granted Critical
Publication of DE60027564T2 publication Critical patent/DE60027564T2/de
Publication of DE60027564T3 publication Critical patent/DE60027564T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60027564T 1999-06-07 2000-06-07 Tek-antagonisten Expired - Lifetime DE60027564T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13788999P 1999-06-07 1999-06-07
US137889P 1999-06-07
PCT/US2000/015706 WO2000075323A1 (en) 1999-06-07 2000-06-07 Tek antagonists

Publications (3)

Publication Number Publication Date
DE60027564D1 true DE60027564D1 (de) 2006-06-01
DE60027564T2 DE60027564T2 (de) 2007-05-10
DE60027564T3 DE60027564T3 (de) 2009-07-23

Family

ID=22479496

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027564T Expired - Lifetime DE60027564T3 (de) 1999-06-07 2000-06-07 Tek-antagonisten

Country Status (14)

Country Link
US (2) US6413932B1 (de)
EP (1) EP1187918B9 (de)
JP (1) JP4587626B2 (de)
AT (1) ATE324444T1 (de)
AU (1) AU783960B2 (de)
CA (1) CA2374851A1 (de)
CY (1) CY1105078T1 (de)
DE (1) DE60027564T3 (de)
DK (1) DK1187918T4 (de)
ES (1) ES2262518T5 (de)
IL (2) IL146482A0 (de)
NZ (1) NZ516258A (de)
PT (1) PT1187918E (de)
WO (1) WO2000075323A1 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
AU2002339863A1 (en) * 2001-08-31 2003-03-18 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
AU2004265226A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
RS53476B (en) 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
CA2571752A1 (en) * 2004-06-25 2006-01-12 Licentia, Ltd. Tie receptor and tie ligand materials and methods for modulating female fertility
US7507748B2 (en) * 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US7973140B2 (en) * 2004-12-21 2011-07-05 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
NO2188313T3 (de) 2007-08-21 2018-03-31
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
EP2247305A4 (de) 2008-01-28 2012-11-14 Medimmune Ltd Stabilisierte angiopoietin-2-antikörper und verwendungen davon
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP2937349B1 (de) 2011-03-23 2016-12-28 Amgen Inc. Fusionierte tricyclische duale inhibitoren von cdk 4/6 und flt3
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
EP3415533A1 (de) * 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2-antikörper und verwendungen davon
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
CN109069639B (zh) 2016-03-08 2022-07-08 詹森生物科技公司 Gitr抗体、方法及用途
UA124474C2 (uk) 2016-12-22 2021-09-22 Емджен Інк. БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP3679040B1 (de) 2017-09-08 2022-08-03 Amgen Inc. Inhibitoren von kras g12c und verfahren zur verwendung davon
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3788038B1 (de) 2018-05-04 2023-10-11 Amgen Inc. Kras-g12c-inhibitoren und verfahren zu deren verwendung
AU2019265822B2 (en) 2018-05-10 2024-07-18 Amgen Inc. KRAS G12C inhibitors for the treatment of cancer
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MA52780A (fr) 2018-06-11 2021-04-14 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
CN108888756A (zh) * 2018-07-25 2018-11-27 韩曙 C16多肽和血管生成素Ang1的应用和应用二者的药物
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021005700A (es) 2018-11-19 2021-07-07 Amgen Inc Inhibidores de kras g12c y metodos de uso de los mismos.
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EP3898592A1 (de) 2018-12-20 2021-10-27 Amgen Inc. Als kif18a-inhibitoren verwendbare heteroarylamide
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
CA3140392A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
BR112021026376A2 (pt) * 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
CA3147276A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
AU2020372881A1 (en) 2019-10-28 2022-06-09 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
MX2022005360A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
CR20220240A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
TW202132271A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
KR20220124768A (ko) 2020-01-07 2022-09-14 레볼루션 메디슨즈, 인크. Shp2 억제제 투여 및 암 치료방법
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
WO2022014640A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
JP2023541916A (ja) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
EP4334321A1 (de) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras-inhibitoren
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
CN117769554A (zh) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1411092A (en) * 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
WO1993014124A1 (en) 1992-01-09 1993-07-22 Helsinki University Holding, Ltd. Tie, a novel endothelial cell receptor tyrosine kinase
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
AU4651893A (en) 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
US5681714A (en) 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
JPH06315382A (ja) 1993-05-06 1994-11-15 Toshio Suda Ｔｉｅ−２受容体をコードするｄｎａ及びｔｉｅ−２受容体
WO1995013387A1 (en) 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tie-2, a novel receptor tyrosine kinase
AUPM379494A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
EP0854185A3 (de) 1994-12-23 1998-10-21 Ludwig Institute For Cancer Research Rezeptor-Proteine zu Bestimmungszwecke und Liganden
AU715621B2 (en) 1995-04-06 2000-02-03 Regeneron Pharmaceuticals, Inc. TIE-2 ligands, methods of making and uses thereof
US6033903A (en) * 1995-06-02 2000-03-07 Applied Research Systems, ARS Holding N.V. Method of expressing and secreting soluble extracellular domains of human gonadotropin hormone receptors
EP0965637B1 (de) * 1996-05-02 2005-07-20 Mochida Pharmaceutical Co., Ltd. Fas ANTIGEN-DERIVATE
WO1998018914A1 (en) 1996-10-31 1998-05-07 Duke University Soluble tie2 receptor
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies

Also Published As

Publication number Publication date
WO2000075323A1 (en) 2000-12-14
NZ516258A (en) 2004-02-27
EP1187918A1 (de) 2002-03-20
JP2003501090A (ja) 2003-01-14
IL146482A (en) 2010-11-30
DE60027564T3 (de) 2009-07-23
AU5328200A (en) 2000-12-28
EP1187918B9 (de) 2009-08-19
ES2262518T3 (es) 2006-12-01
IL146482A0 (en) 2002-07-25
EP1187918B1 (de) 2006-04-26
CY1105078T1 (el) 2009-11-04
ES2262518T5 (es) 2009-05-08
US20070025993A1 (en) 2007-02-01
DE60027564T2 (de) 2007-05-10
PT1187918E (pt) 2006-08-31
DK1187918T3 (da) 2006-08-21
US6413932B1 (en) 2002-07-02
CA2374851A1 (en) 2000-12-14
ATE324444T1 (de) 2006-05-15
AU783960B2 (en) 2006-01-05
DK1187918T4 (da) 2009-02-23
JP4587626B2 (ja) 2010-11-24
EP1187918B2 (de) 2009-01-14

Similar Documents

Publication Publication Date Title
DK1187918T3 (da) TEK-antagonister
NO20034056D0 (no) Proliferative sykdommer
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
HRP20080467A2 (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
DK1202736T3 (da) Nikotin i terapeutisk angiogenese og vasculogenese
NO20001598L (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
WO2006015060A3 (en) Isoindoline compounds and methods of their use
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE333882T1 (de) Zusammensetzungen zur hemmung der angiogenese
DE59708265D1 (de) Neue in 6-position substituierte phenanthridine
ATE344031T1 (de) Thrombopoietin-mimetika
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DK1220852T3 (da) Substituerede diazepaner
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
TR200200278T2 (tr) Kalsilitik bileşimler
DK1185293T3 (da) IL6RIL6-kimær til behandling af neurodegenerative sygdomme
BR0111785A (pt) Composições e métodos para tratamento de candidìase

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN

8366 Restricted maintained after opposition proceedings